Project Mercury was launched to rethink the treatment of Benign Prostatic Hyperplasia (BPH), offering a simple treatment option for patients who need immediate relief from lower urinary tract symptoms (LUTS) with minimal side effects and preserving sexual function.
Around 50% of men aged 50 and above experience LUTS attributable to BPH. In men over 80 years old, this rises to over 80%. Symptoms include increased frequency of urination, nocturia, hesitancy, urgency, and weak urinary stream.
Current BPH treatment methods are associated with a multitude of side effects including sexual dysfunction. Treatment with medication is commonly linked to several potential negative side effects such as dizziness, hypotension, erectile dysfunction, and incomplete symptom relief. Surgical treatment options, including the gold standard transurethral resection of the prostate (TURP) or laser surgery, can offer permanent symptom relief, but may lead to irreparable damage to sexual function. Other minimally invasive treatment options may require higher levels of anesthesia, significant use of pain medication, cause permanent damage to the prostatic tissue, and in some cases may require the temporary need for a urinary catheter after the procedure.
Project Mercury is designed to widen the narrowed prostatic urethra tissue creating an open urethral lumen for normal urinary flow. This structure can be deployed using a commercially available standard flexible cystoscope in hospital outpatient settings and ambulatory surgery center (ACS).
KOL and physicians have positive comments on the features of Mercury design:
Medeon firmly believes Project Mercury represents a significant leap forward in the treatment of LUTS caused by BPH. Clinical studies and regulatory approvals are ongoing.